Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Drop in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the recipient of a significant drop in short interest in October. As of October 30th, there was short interest totaling 54,541 shares, a drop of 56.8% from the October 15th total of 126,324 shares. Based on an average daily volume of 67,646 shares, the days-to-cover ratio is currently 0.8 days. Approximately 6.5% of the shares of the stock are sold short.

Moleculin Biotech Price Performance

Shares of MBRX stock traded down $0.19 during mid-day trading on Friday, hitting $7.87. The stock had a trading volume of 9,899 shares, compared to its average volume of 43,939. Moleculin Biotech has a 12-month low of $3.23 and a 12-month high of $229.40. The firm’s 50-day moving average is $9.94 and its two-hundred day moving average is $36.71.

Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($9.59) EPS for the quarter, missing analysts’ consensus estimates of ($8.87) by ($0.72). On average, analysts predict that Moleculin Biotech will post -47.40 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, October 15th. Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, HC Wainwright decreased their price objective on shares of Moleculin Biotech to $60.00 and set a “buy” rating for the company in a research note on Friday, August 28th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $60.00.

View Our Latest Stock Analysis on MBRX

Moleculin Biotech Company Profile

(Get Free Report)

Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.

Further Reading

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.